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Tetanus is a vaccine-preventable, global infectious
disease caused by Clostridium tetani, with signifi-
cant morbidity and mortality. The global status
of serological immunity against tetanus varies be-
tween countries as a result of different national
vaccination policies and methods, and the crite-
ria used for determination of serum levels of
tetanus antitoxin. For example, protective immu-
nity was noted in 15.7% of people in Turkey and
23–32% of those in Denmark aged > 60 years,
while 53–80% of people aged > 60 years residing
in the United States, England, Wales and Sweden,
and < 75% of Australians aged > 50 years were
immune to tetanus.1–6
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Background/Purpose: Tetanus is caused by Clostridium tetani, and is a vaccine-preventable infectious disease.
The purpose of this study was to investigate the degree of protective tetanus immunity among adolescents
and adults in Taiwan, which may provide valuable information for recommendations for tetanus vaccination
strategy.
Methods: Individuals aged 16 years or older who were visiting a local hospital for health examinations were
invited to participate in the study. Participants’ serum levels of tetanus antitoxin were measured. A standard
questionnaire was used to collect demographic data and information about risk factors. The prevalence of
protective tetanus immunity in various age groups was described and sociodemographic factors that poten-
tially influenced the degree of tetanus immunity were analyzed.
Results: Overall, 326 persons were included. Of these, 217 (67%) had never received a toxoid booster,
while 109 (33%) had received a booster at least once. Among all participants, 95% had protective tetanus
antitoxin levels (≥ 0.11 IU/mL), and 60% had protective antitoxin levels without the need of an immediate
booster, i.e. ≥ 0.51 IU/mL. Among 70 participants aged > 60 years, 89% had protective antitoxin levels
≥ 0.11 IU/mL, and 31% had protective antitoxin levels ≥ 0.51 IU/mL. Tetanus antitoxin levels declined with
age. Male gender, birth after 1955, and prior receipt of toxoid booster(s) were independently associated
with protective tetanus immunity (≥ 0.51 IU/mL) by multivariate analysis. Compared with those without
tetanus toxoid boosters, individuals with a prior booster had higher antitoxin levels. The percentage of peo-
ple with protective immunity declined if the interval between the last toxoid booster increased.
Conclusion: Waning immunity to tetanus was observed after primary tetanus vaccination or toxoid booster.
The public health policy that one dose of toxoid booster after primary vaccination should be emphasized for
continuing protection against tetanus. [J Formos Med Assoc 2009;108(5):395–401]
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Tetanus toxoid for post-traumatic prophylaxis
was introduced in Taiwan after 1953. In Taiwan,
according to the National Children’s Vaccine Pro-
gram, diphtheria–pertussis–tetanus (DPT) vaccine
was given routinely to 2-, 4-, 6- and 18-month-old
children as primary vaccination since 1955. As a
result of implementation of DPT vaccination pro-
grams and improvement in obstetrical practices
and neonatal care, tetanus has occurred mainly in
people older than 65 years, rather than neonates or
children, in recent decades.7,8 From 2000 to 2005,
according to data from the Centers of Disease Con-
trol (CDC) Taiwan, there were 102 reported cases
of tetanus.9 Patients aged ≥ 60 years accounted
for 60% of tetanus cases. The mortality rate of teta-
nus among these patients was substantial, ranging
from 10% to 22%.7,8 Waning immunity to tetanus
in the elderly and poor wound management prac-
tices by primary care physicians were suspected to
be contributory factors.7 The CDC in the United
States recommended that tetanus toxoid boosters
should be given every 10 years after primary vacci-
nation, to maintain protective immunity against
tetanus.10 However, in Taiwan, most adults did
not receive booster doses unless they had physi-
cal trauma. At present, there is no regular vaccine
program against tetanus for the elderly.
The latest data in Taiwan about serum levels of
tetanus antitoxin among neonates and children
were reported in 1987.11 However, the information
about tetanus immunity in adults is scant. The pur-
pose of this study was to investigate the degrees
of protective tetanus immunity among adolescents
and adults, which may provide valuable informa-
tion for recommendations for tetanus vaccination
strategy.
Materials and Methods
A prospective study was performed in National
Cheng Kung University Hospital (NCKUH),
Douliou Branch, between March 2006 and Novem-
ber 2006, which was approved by the Institutional
Review Board of NCKUH. Individuals aged ≥ 16
years who were visiting a local hospital for health
examinations were invited to participate. Partici-
pants’ serum levels of tetanus antitoxin were
measured. Those not sure of their status of toxoid
vaccination were excluded. After obtaining in-
formed consent, blood samples were collected, and
sera were stored at –20°C until use. Meanwhile,
a standard questionnaire, including items of resi-
dency, occupation, previous soil or water expo-
sure, previous histories of military service, injury
or tetanus, and the status of toxoid boosters in
adolescence or adulthood, was filled in based on
face to face interviews. Wounds caused by punc-
ture with rusted iron materials or animal bites, or
those contaminated by soil were regarded as dirty.
For convenience, among participants who did not
receive primary tetanus vaccination in infancy,
such as those born before the initiation of the DPT
vaccination program in 1955, toxoid injection
later in life was also considered as a booster dose.
Serum level of tetanus antitoxin was mea-
sured by an enzyme-linked immunosorbent
assay (ELISA) (Novatec, Dietzenbach, Germany).
Diluted serum was dispensed into each well, and
incubated for 1 hour at 37°C, followed by three
washes in the washing solution. Tetanus anti-IgG
conjugate was then added, and the wells were in-
cubated for 30 minutes at room temperature in the
dark, and washed again. Tetramethylbenzidine
substrate was then added to each well, and incu-
bated for 15 minutes at room temperature in the
dark. The absorbance of each specimen at 450/
620 nm was measured by an ELISA microwell
plate reader (Murex Diagnostics, Dartford, UK).
The serum tetanus antitoxin levels were in-
terpreted as defined previously by Schroder 
and Kuhlmann.12 An antitoxin concentration
≥ 0.11 IU/mL was regarded as protective immu-
nity. According to the manufacturer’s instructions,
an immediate booster and antitoxin measure-
ment 4–6 weeks later is recommended if anti-
toxin level is 0.11–0.5 IU/mL. A booster is not
required immediately and antitoxin measure-
ment 2 years later is suggested if antitoxin level 
is 0.51–1.0 IU/mL. Long-term protection can be
achieved and antitoxin measurement 10 years later
is recommended if antitoxin level is > 5.0 IU/mL.
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The prevalence of protective tetanus immunity was
described in various age groups. Sociodemographic
factors potentially influencing the degree of tet-
anus immunity were analyzed.
The χ2 test was used for qualitative data, and
Student’s t test for quantitative data. Linear re-
gression was used for correlation analysis. A value
of p < 0.05 was considered to be significant.
Results
Demographic characteristics of participants
Between March 2006 and November 2006, 336 in-
dividuals agreed to participate in this study initially.
Eleven persons who were not sure about their im-
mune and tetanus booster status were excluded
from this study. Finally, 325 individuals, including
147 men and 179 women, were included. One
woman received a toxoid booster because of trau-
ma and her serum was obtained 30 days later, and
she was counted twice. Therefore, there were a total
of 326 participants. Those aged 40–59 years were
divided into two age groups: 40–50 and 51–59
years, because the DPT National Children’s Vacci-
nation Program in Taiwan was initiated among par-
ticipants aged ≤ 51 years old. The case numbers
in different age groups are shown in Table 1. One
third (109, 33.4%) of 326 participants recalled re-
ceiving at least one toxoid booster. Of these, 86
(78.9%) had received one booster, 18 (16.5%),
two, and five (4.5%), three or more. Overall, 55%
of men and 76% of women, which accounted for
two thirds of all participants, denied the receipt
of a toxoid booster after childhood. None of the
participants enrolled had a history of tetanus.
Tetanus immunity among participants
Among 326 participants, 95% had a protective
antitoxin level (≥ 0.11 IU/mL), and 60% had 
a protective antitoxin level that did not require
an immediate booster (≥ 0.51 IU/mL). Among 
70 participants aged > 60 years, 89% had pro-
tective antitoxin levels (≥ 0.11 IU/mL), and 31%
had protective antitoxin level (≥ 0.51 IU/mL)
(Table 2). Mean antitoxin level declined with age,
from 4.83 IU/mL in those aged 16–19 to 0.82–
0.87 IU/mL in those aged > 51 years (Figure 1).
Tetanus immunity among participants
without toxoid booster
Among 217 participants without toxoid boosters
after childhood, 96–100% of those aged ≤50 years
had protective antitoxin levels (≥ 0.11 IU/mL),
while 83–88% of those > 51 years had protective
antitoxin levels (Figure 2). The proportion of peo-
ple with protective immunity and no need for an
immediate booster, i.e. antitoxin levels ≥ 0.51 IU/
mL, declined with age. The ratio decreased from
100% in those aged 16–19 years, to 52% in those
aged 40–50 years, and to 19% in those aged ≥70
years (correlation r = 0.9, p = 0.001). Likewise, a
similar trend in decline of mean antitoxin level
with age was observed. The level decreased from
3.31 IU/mL in those aged 16–19 years to 0.31–
0.81 IU/mL in those aged > 51 years (Figure 1).
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Table 1. Demographic characteristics and history of tetanus vaccine booster
Total case no. (case no. with booster, %)
Age (yr)
Males Females All
16–19 15 (3, 20%) 8 (3, 38%) 23 (6, 26%)
20–29 53 (29, 55%) 56 (9, 16%) 109 (38, 35%)
30–39 15 (10, 67%) 25 (5, 2%) 40 (15, 38%)
40–50 15 (6, 40%) 36 (12, 33%) 51 (18, 35%)
51–59 17 (7, 41%) 16 (3, 19%) 33 (10, 30%)
60–69 13 (5, 38%) 13 (4, 31%) 26 (9, 35%)
≥ 70 19 (6, 32%) 25 (7, 28%) 44 (13, 30%)
Total 147 (66, 45%) 179 (43, 24%) 326 (109, 28%)
Host factors associated with protective
immunity
Men born after 1955, who had a history of 
toxoid boosters, military service, dirty wounds,
or frequent soil exposure, were significantly more
likely to have antitoxin levels ≥ 0.51 IU/mL, by the
univariate analysis (Table 2). However, only male
gender, birth after 1955, and prior receipt of tetanus
toxoid boosters were independently associated
with protective antitoxin levels (≥ 0.51 IU/mL),
by multivariate analysis. In addition, people who
were born before 1955 were involved more fre-
quently with soil or garden work than those
born after 1955 (61% vs. 14%, p < 0.001).
Immunity after booster injection
Compared with 217 participants without toxoid
boosters after childhood, 109 who had ever 
received a toxoid booster had higher antitoxin lev-
els (p< 0.05) in all age groups (Figure 1). The ratio
of participants with protective immunity declined,
as the interval between the last toxoid booster and
the time of antitoxin determination increased.
Among 109 people with tetanus toxoid boosters,
59 received the last booster within 5 years, and
27, 16, and 7 people received it 6–10, 11–20, and
21–30 years ago, respectively. Of people receiving
the last toxoid booster within 5 years, 6–10, 11–20,
and 21–30 years ago, 86, 81, 50 and 57%, respec-
tively, of them had antitoxin levels ≥ 0.51 IU/mL.
Only 13% of people who received their last tox-
oid booster 11–20 years ago had antitoxin levels
≥ 5 IU/mL, which signified long-term protection
of > 10 years. In addition, tetanus antitoxin level
in a 39-year-old woman increased from 0.4 to
17.9 IU/mL at 30 days following a toxoid booster.
C.J. Wu, et al
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Table 2. Host factors associated with protective tetanus immunity
Case no. with protective Case no. with protective 
Total case no. immunity (anti-toxin p† immunity (anti-toxin p†
≥ 0.11 IU/mL), (%) ≥ 0.51 IU/mL), (%)
All participants 326 311 (95) 195 (60)
Gender 0.1187 < 0.001‡
Male 147 143 (97) 108 (73)
Female 179 168 (94) 87 (49)
Previous military service 0.781 0.016
Yes 105 101 (96) 73 (70)
No 221 210 (95) 122 (55)
Year of birth* < 0.001 < 0.001‡
Before 1955 102 89 (87) 34 (33)
After 1955 224 222 (99) 161 (72)
Tetanus booster 0.401 < 0.001‡
Yes 109 106 (97) 85 (78)
No 217 205 (95) 110 (51)
Soil/garden work 0.015 0.018
Yes 93 84 (90) 46 (49)
No 233 227 (97) 149 (63)
History of dirty wounds 0.793 < 0.001
Yes 148 142 (96) 106 (72)
No 178 169 (95) 89 (50)
*Diphtheria–pertussis–tetanus vaccine program commenced since 1955; †univariate analysis; ‡multivariate analysis, male gender, birth after 1955, and
having ever received a tetanus booster were associated with protective tetanus immunity that did not require an immediate booster dose (tetanus antitoxin
levels ≥ 0.51 IU/mL) (p < 0.001 for each factor).
Discussion
Methods for in vitro determination of serum tetanus
antitoxin include the passive hemagglutination
test, ELISA and radioimmunoassay. ELISA was used
in our study because it is simple, sensitive, rapid,
and inexpensive.12 Several ELISAs have been de-
scribed in the literature, and the cut-off values for
antibody titers differ between kits. The serum teta-
nus antitoxin levels determined by ELISA in our
study were interpreted as previously defined by
Schroder and Kuhlmann,12 in which antitoxin
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Figure 1. Comparison of tetanus antitoxin levels between participants with or without toxoid booster(s) and among all
participants. Bars represent mean values. Participants who had ever received a toxoid booster were associated with signifi-
cantly higher antitoxin levels than those who had not, in all age groups except 60–69 years (p < 0.05).
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Figure 2. Serum tetanus antitoxin levels in different age groups among 217 participants without a booster, and the ratio
of protective tetanus immunity defined as serum antitoxin ≥ 0.11 IU/mL or ≥ 0.51 IU/mL.
levels ≥ 0.11 IU/mL were considered as protective.
However, a toxoid booster is still suggested if the
level falls within the range 0.11–0.5 IU/mL. Imme-
diate booster is not required if the level is ≥0.51IU/
mL. As a result, both protective levels (≥0.11IU/mL
and ≥0.51 IU/mL) were analyzed in our study, and
the latter represented protective immunity that did
not require an immediate booster.
We demonstrated that tetanus toxoid booster
was associated with higher tetanus antitoxin 
levels. First, among all participants, those who
had ever received a toxoid booster were shown
more frequently to have protective antitoxin level
(≥ 0.51 IU/mL) by multivariate analysis. Second,
the antitoxin levels among individuals who had
received a toxoid booster during childhood or
adolescence were higher than those without a
booster in different age groups. Furthermore, we
found in a 38-year-old woman that tetanus anti-
toxin level increased from 0.4 IU/mL to 17.9 IU/mL
at 30 days following a toxoid booster. All of the
above findings implied that the toxoid booster
helped to achieve an adequate antitoxin level.
However, even with a toxoid booster, the protec-
tive effect was not life-long and waned with time.
The duration of protection with a booster varied
between individuals. In general, we found that
> 80% of them had protective antitoxin levels
that did not require an immediate booster, i.e.
≥ 0.51 IU/mL, if they had received the latest
booster within 10 years, while only half had pro-
tective levels if they received their latest booster
> 10 years ago. The waning immunity after 10
years highlighted the importance of receiving
toxoid boosters every 10 years after primary vac-
cination, as recommended by the CDC in the
USA for continuing protection against tetanus.10
Participants who were born after 1955 when
the National Children’s Vaccination Program in
Taiwan was initiated were more immune to
tetanus. Whether this phenomenon resulted from
the long-term protective effect of primary DPT
vaccination could not be clarified in the present
study. This is because aging per se was a factor 
associated with lower antitoxin level, which was
shown by the waning immunity with age after
primary vaccination among those who did not
receive a booster. However, the efficacy of tetanus
toxoid has been demonstrated in studies from
many countries, and ranges from 80% to 100%.13
In Taiwan, the high efficacy of the initial three
doses of primary DPT vaccination was demon-
strated by the fact that 99% of 104 children aged
12–23 months possessed tetanus antitoxin con-
centrations above protective levels.14 However,
antitoxin level declined with age regardless of
whether the subjects had received a toxoid
booster. As a result, primary tetanus vaccination
followed by subsequent toxoid booster is war-
ranted to achieve adequate, life-long immunity
against tetanus. The older a person is, the greater
the necessity of receiving a tetanus booster because
of waning immunity in the older age group.
We showed that male subjects had higher im-
munity against tetanus, which has also been
shown in previous studies.4,15 This may be because
higher accident rates among men increase the
probability of receiving a tetanus booster, which
results in higher protective immunity, as seen in
a study in the United States.4 Another possible
explanation is immunization during military ser-
vice.15,16 However, toxoid booster was not given
routinely during military service in our country,
and men were not found to experience more
trauma or receive more toxoid booster doses than
women in our study. Neither factor was signifi-
cant in multivariate analysis. Further work is
needed to elucidate the reasons for greater tetanus
immunity among men than woman.
People with frequent exposure to soil and gar-
den work are at risk of contact with C. tetani spores
through puncture or scratch wounds, and of de-
veloping tetanus, if they do not have adequate
immunity. From 2000 to 2005, according to data
from CDC Taiwan, there were 102 reported cases
of tetanus.9 Patients aged ≥ 60 years accounted
for 60% of tetanus cases, and 89% resided in
rural areas. We found that participants who were
exposed frequently to soil seemed to be associated
with lower rather than increasing antitoxin levels.
Such an association was absent in the multivariate
analysis. This may have been because a greater
C.J. Wu, et al
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number of older people were involved with soil
and gardening in the present study. The tetanus
antitoxin levels were lower in older people, and
age was a possible confounder of the association
between low antitoxin levels and frequent soil ex-
posure. Elderly people tended to lose their pro-
tection against tetanus because tetanus antitoxin
levels declined with time, which may explain why
older people accounted for most of the tetanus
cases in Taiwan. This highlights the importance
of maintaining adequate tetanus immunity by tox-
oid boosters in older people who are involved
with soil and gardening.
Some authors have reported natural immunity
to tetanus, because of the presence of tetanus anti-
toxin in the sera of persons who have not received
tetanus toxoid.17,18 Likewise, we found that some
people born before the initiation of childhood teta-
nus vaccination, who never received tetanus toxoid,
did have protective antitoxin levels. It has been
proposed that natural tetanus immunity can be
induced by sub-lethal doses of tetanus toxin or
by fragments of toxin released from C. tetani lo-
cated in the digestive tract, as a result of ingesting
tetanus spores.17 However, the clinical implica-
tions of natural immunity remain unresolved.
In conclusion, waning immunity to tetanus was
observed after childhood tetanus vaccination or
toxoid boosters. A vaccination strategy that in-
volves a toxoid booster after primary vaccination
should be emphasized to maintain protective tet-
anus antitoxin levels during adulthood, especially
among older people at high risk for tetanus.
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